Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Circulating Tumour DNA as a Marker of Residual Disease and Response to Adjuvant Chemotherapy in Stage I-IV Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer (EOC)

NCT03691012 is registered in ClinicalTrials.gov with Walter and Eliza Hall Institute of Medical Research as lead sponsor.

NCT NCT03691012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03691012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Circulating Tumour DNA as a Marker of Residual Disease and Response to Adjuvant Chemotherapy in Stage I-IV Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer (EOC)
Lead sponsor
Walter and Eliza Hall Institute of Medical Research
Phase
Observational
Overall status
Unknown status
Start date
May 9, 2017
Completion date
May 9, 2025
Enrollment
118 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer